US2019388391A1PendingUtilityA1

Novel erythromelalgia treatment

39
Assignee: CONVERGENCE PHARMACEUTICALSPriority: Oct 3, 2014Filed: Jan 22, 2019Published: Dec 26, 2019
Est. expiryOct 3, 2034(~8.2 yrs left)· nominal 20-yr term from priority
Inventors:Valerie Morisset
A61P 29/00A61P 25/02A61K 31/401C12Q 2600/106C12Q 2600/156C07D 207/04C12Q 1/6883
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to the treatment of erythromelalgia comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method of treating erythromelalgia, comprising administering to a subject in need thereof a therapeutically effective amount of (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof. 
     
     
         16 . The method according to  claim 15 , wherein the (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or pharmaceutically acceptable salt thereof is (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide hydrochloride. 
     
     
         17 . The method according to  claim 15 , wherein the subject is a human. 
     
     
         18 . The method according to  claim 15 , wherein the erythromelalgia is primary erythromelalgia. 
     
     
         19 . The method according to  claim 15 , wherein the erythromelalgia is secondary erythromelalgia. 
     
     
         20 . A method of treating erythromelalgia, comprising administering to a subject in need thereof a pharmaceutical composition comprising (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof. 
     
     
         21 . The method according to  claim 20 , wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents, or excipients, or a combination thereof. 
     
     
         22 . The method according to  claim 20 , wherein the (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or pharmaceutically acceptable salt thereof is (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide hydrochloride. 
     
     
         23 . The method according to  claim 20 , wherein the erythromelalgia is primary erythromelalgia. 
     
     
         24 . The method according to  claim 20 , wherein the erythromelalgia is secondary erythromelalgia.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.